Compare TransMedics Group Inc (TMDX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs United Microelectronics Corp — how do they compare? TransMedics Group Inc trades at $74.83 (market cap $2.54B), while United Microelectronics Corp trades at $21.21 (market cap $51.00B). The key difference: United Microelectronics Corp is far larger — about 20.1× TransMedics Group Inc's market cap, and United Microelectronics Corp pays a 2.03% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | UMC | |
|---|---|---|
Market Cap | $2.54B | $51.00B |
Sector | Technology | Technology |
52-Week High | $150.42 | $28.02 |
52-Week Low | $61.99 | $6.58 |
Enterprise Value | $2.94B | $48.57B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
UMC trades at $20.41, down 3.95% for the day, with a bearish technical signal but oversold RSI readings. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains strong profitability with a 20.25% net margin. Recent news highlights mass production of silicon photonics ICs and a new 14nm eHV platform, signaling innovation in semiconductor technology.
Outlook is mixed: analyst consensus leans Hold (53%) amid high valuation multiples (P/E 34.5), but earnings beats and specialty tech growth offer upside. Risks include competitive pressures and margin compression from 32.1% in 2022 to 17.0% in 2025. Cash flow improved to $5.66B net in 2025, supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
